ROSEN, SKILLED INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL GlobeNewswire August 10, 2025 NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, […]

SRPT DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SRPT

(NASDAQ:SRPT), NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline. SO WHAT: If

SRPT DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SRPT

SRPT DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SRPT GlobeNewswire August 10, 2025 NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of

DDD FINAL DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages 3D Systems Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important August 12 Deadline in Securities Class Action – DDD

(NYSE:DDD), NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of 3D Systems Corporation (NYSE: DDD) between August 13, 2024 and May 12, 2025, both dates inclusive (the “Class Period”), of the important August 12, 2025 lead plaintiff deadline. SO WHAT: If

DDD FINAL DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages 3D Systems Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important August 12 Deadline in Securities Class Action – DDD

DDD FINAL DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages 3D Systems Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important August 12 Deadline in Securities Class Action – DDD GlobeNewswire August 10, 2025 NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm,

CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Capricor Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK CITY, NY / ACCESS Newswire / August 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ:CAPR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against

Multilingual Conversational Speech Language Model (MLC-SLM) workshop at Interspeech 2025

As part ofInterspeech 2025,Nexdatawill host theMLC-SLM WorkshoponAugust 22atDock 14, Rotterdam Ahoy Convention Centre. This workshop is dedicated to advancing multilingual conversational speech AIby addressing a pressing challenge in the field: the lack of multilingual, context-rich dialogue data for training LLM-basedspoken dialogue systems. About the Workshop At the heart of the workshop is the MLC-SLMChallenge, a

IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio(R) in Combination with KEYTRUDA(R) (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

(NASDAQ:IOBT), NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August 11, 2025, at 8:30 AM ET to disclose the topline results of the pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) of its investigational, immune-modulatory, off-the-shelf

IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio(R) in Combination with KEYTRUDA(R) (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio(R) in Combination with KEYTRUDA(R) (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma GlobeNewswire August 10, 2025 NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference

Levi & Korsinsky Urges 3D Systems Corporation (DDD) Shareholders to Act Before Lead Plaintiff Deadline August 12, 2025

NEW YORK, NY / ACCESS Newswire / August 10, 2025 / If you suffered a loss on your 3D Systems Corporation (NYSE:DDD) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/3d-systems-corporation-lawsuit-submission-form?prid=160628&wire=1&utm_campaign=19 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

Scroll to Top